Bosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous...
10 KB (633 words) - 12:29, 5 August 2024
Bosutinib's activity was first described in 2001 and it was disclosed as an Abl kinase inhibitor in 2003. At first it was believed that bosutinib was...
56 KB (6,470 words) - 06:03, 24 October 2024
approved in South Korea for people resistant to or intolerant of imatinib. Bosutinib received US FDA and EU European Medicines Agency approval on 4 September...
34 KB (3,877 words) - 13:44, 25 October 2024
(ALK) Non-receptor bcr-abl Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib Dasatinib) Janus kinase Baricitinib Fedratinib...
12 KB (821 words) - 02:57, 12 October 2024
Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib (Iclusig) Asciminib (Scemblix) Bortezomib (Velcade)...
20 KB (2,234 words) - 01:21, 22 July 2024
available inhibitors to treat CML are imatinib, dasatinib, nilotinib, bosutinib and ponatinib. Gastrointestinal stromal tumors (GIST) are known to withstand...
43 KB (5,251 words) - 10:44, 24 June 2024
injectables such as the EpiPen. On September 4, 2012, the FDA approved bosutinib (Bosulif) for chronic myelogenous leukemia (CML), a rare type of leukemia...
168 KB (14,575 words) - 20:40, 12 November 2024
bornelone (INN) Borofax bortezomib (USAN) Boruzu Bosatria bosentan (INN) bosutinib (USAN, INN) botiacrine (INN) Botox Boudreaux's Butt Paste boxidine (INN)...
7 KB (387 words) - 05:56, 19 October 2024
Ixabepilone L01EA01 Imatinib L01EA02 Dasatinib L01EA03 Nilotinib L01EA04 Bosutinib L01EA05 Ponatinib L01EA06 Asciminib L01EB01 Gefitinib L01EB02 Erlotinib...
12 KB (877 words) - 15:36, 25 January 2024
(ALK) Non-receptor bcr-abl Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib Dasatinib) Janus kinase Baricitinib Fedratinib...
12 KB (758 words) - 23:46, 14 March 2024